PEAK6 Group’s Ultragenyx Pharmaceutical RARE Stock Holding History

PEAK6 Group’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-3,500	Closed	-$162K	–	4822
2017 Q4	$162K	Hold	3,500	–	–	﹤0.01%	3287
2017 Q3	$186K	Buy	+3,500	New	+$207K	﹤0.01%	3356
2017 Q2	–	Sell	-7,500	Closed	-$508K	–	4922
2017 Q1	$508K	Buy	+7,500	New	+$572K	﹤0.01%	2245
2016 Q4	–	Sell	-200	Closed	-$14K	–	5023
2016 Q3	$14K	Hold	200	–	–	﹤0.01%	4139
2016 Q2	$10K	Buy	+200	New	+$12.9K	﹤0.01%	4139
2015 Q4	–	Sell	-22,900	Closed	-$2.21M	–	5198
2015 Q3	$2.21M	Buy	22,900 +20,100	+718%	+$2.3M	0.01%	1502
2015 Q2	$287K	Buy	+2,800	New	+$217K	﹤0.01%	3358

Other funds holding RARE

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

PEAK6 Group's RARE Position: Q1 2018 in Review

PEAK6 Group sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2018, closing a stake of 1,300 shares — an estimated $60K sold.

PEAK6 Group first reported a position in RARE in Q3 2015 and held it in 4 quarters. The position peaked at $997K in Q3 2015. 165 funds tracked by Wall St. Rank hold RARE as of Q1 2018.

PEAK6 Group reported no remaining Ultragenyx Pharmaceutical position as of Q1 2018 after selling out during the quarter.
PEAK6 Group sold 1,300 Ultragenyx Pharmaceutical shares in Q1 2018, an estimated $60K.
PEAK6 Group first reported a position in Ultragenyx Pharmaceutical in Q3 2015 and held it in 4 quarters.
PEAK6 Group's Ultragenyx Pharmaceutical position peaked at $997K in Q3 2015.
165 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2018.

Based on PEAK6 Group's 13F filing for Q1 2018, filed 15 May 2018.